Learn more about Peter Attia’s digital program
Reassuring new data on statin-induced Lp(a) elevation
Statin therapy is known to raise Lp(a) particle concentration in some patients, but how does this impact the overall effect of these medications on ASCVD risk?
#229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB
“Not everybody dies from atherosclerosis, but… everybody dies with it.” —Peter Attia
The genetics of PCSK9i nonresponders
A recent case study shines light on why some individuals are resistant to PCSK9 inhibitors.
Heart Disease: Labs & Diagnostic Tests
This video clip is from episode #203 — AMA #34: What causes heart disease? — originally released on April 18,…
First Case of Human PCSK9 Gene-Editing
Ultimately, the long-term benefits of lowering apoB through a one-time treatment may make this not only a viable future option, but potentially an intervention that could change preventive cardiovascular medicine.
The connection between sleep and heart disease
This audio clip is from episode #48 with Matthew Walker, Ph.D., on sleep – Part II of III: Heart disease, cancer,…
Cumulative effects of LDL-C reduction in mitigating cardiovascular risk
Atherosclerotic cardiovascular disease (ASCVD) is currently the leading cause of death in the U.S. One of the most effective ways to reduce risk of ASCVD mortality is reduction of apoB particle number, typically estimated by LDL cholesterol (LDL-C) concentrations.
Lp(a) and CVD risk & clinical tests to measure Lp(a)
This video clip is from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D., originally…
Can cocoa help prevent cardiovascular death?
A recent study explored whether supplementation with the beneficial compounds in cocoa could have a clinically-relevant effect on ASCVD.
Peter’s approach to managing patients with high Lp(a)
This video is a clip from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D.,…